Navigation Links
FDA Approves New 3000 IU Vial Size for Kogenate(R) FS, antihemophilic factor (recombinant)
Date:8/7/2009

WAYNE, N.J., Aug. 7 /PRNewswire/ -- Today, Bayer HealthCare Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved a 3000 IU (international unit) vial size of Kogenate(R) FS, antihemophilic factor (recombinant). The new vial size offers greater convenience for patients with hemophilia A who require a higher dose.

The 3000 IU vial may eliminate the need for combining smaller vials and may allow some patients to achieve more precise dosing. It is available in a conventional vial-to-vial reconstitution system and in Kogenate FS Grab & Go packaging with BIO-SET(R), a compact and complete reconstitution system. Grab & Go includes the Terumo(R) SURFLO(R) Infusion Set with filter and other materials necessary for safe reconstitution and fast recombinant factor VIII treatment in a small, tamper-evident box with anticounterfeiting features.

"The availability of Kogenate FS in a 3000 IU vial demonstrates Bayer's commitment to adolescent and adult patients, who are more likely to have a need for higher doses and who will appreciate the greater convenience of the larger vial," said Joni Osip, RN, MS, Hemophilia Nurse Coordinator, Center for Bleeding and Clotting Disorders at the University of Minnesota Medical Center, Fairview, in Minneapolis.

The Kogenate FS line of products now includes the following vial sizes: 250, 500, 1000, 2000 and 3000 IU. Kogenate FS has one of the smallest diluent volumes available. The 250, 500 and 1000 IU vial sizes are provided with 2.5 mL of diluent; the 2000 and 3000 IU vial sizes are reconstituted with 5 mL of diluent. The 3000 IU vial size is now part of the Kogenate FS Free Trial Program, which is open to people with hemophilia A who meet program eligibility criteria.

"The 3000 IU vial size is being offered in response to customer needs and
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... Alzheimer,s disease has been a rapidly evolving pursuit ... latest crook in the research road, scientists have ... proteins associated with the disease. The report, which ... , could have important implications for developing novel ... colleagues explain that for years, research has suggested ...
(Date:4/22/2014)... the New Jersey Institute of Technology (NJIT) today ... the launch of the New Jersey Innovation Institute ... model for business innovation through the leveraging of ... U.S. Senator Cory Booker, Panasonic Corp. of North ... Lieutenant Governor Kim Guadagno, New Jersey Secretary of ...
(Date:4/22/2014)... the last few decades researchers have characterized a set ... and behavior in all types of species, from flies ... identified, but researchers surmise there are more. A team ... of Pennsylvania wondered if big-data approaches could find them. ... by John Hogenesch, PhD, professor of Pharmacology and first ...
(Date:4/22/2014)... Researchers at UT Southwestern Medical Center are making breakthroughs ... , A team of physician-scientists at UT Southwestern ... hormone with natural anti-depressant properties) works inside the brain. ... for depression in the form of a neuroprotective drug ... online in April,s issue of Molecular Psychiatry, ...
(Date:4/22/2014)... women using a newer method of planned sterilization called ... a 10-year period than using the more commonly performed ... and UC Davis has found. , Published online ... study found the higher risk of pregnancy with a ... , "This study provides essential information for women ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3
... March issue of Neurology, the epilepsy drug Valproate has been ... ,For pregnant women with epileptic seizures, often the ... who took the drug in their first trimester of pregnancy ... the study was collected from pregnant women in US and ...
... has for decades focused on finding the underlying genetic ... genes themselves are controlled by components outside the nucleus ... microenvironment," said researcher Maniotis. ,Research finding at ... malignancy also depends on the molecules that surrounds the ...
... adding the drug rasagiline to standard treatment with levodopa ... patients spend suffering from motor fluctuations they experience during ... once-daily oral rasagiline to the drug entacapone, which must ... in around 690 patients. Both of the additional drugs ...
... able to monitor their blood sugar around the clock without ... ,A new device that measures blood sugar by testing ... out by a transdermal low-level electric current -- and then ... effective even in children under age 7. ,Studies were ...
... to suggest that supplementing the diet with vitamin E ... study published In Journal Of American Medical association, says ... something very different. ,The researchers had studied ... or HOPE centers between 1993 and 1999, and the ...
... says that oil from the fishes contains a property that ... Salmon, if are taken in a diet supplemented by low ... disease and arthritis. In case of absence of fish, a ... trick. ,Trials have shown previously that omega-3 fatty acids ...
Cached Medicine News:Health News:Cell’s microenvironment linked to cancer 2
(Date:1/15/2014)... DALLAS , Jan. 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com ... to its store . (Photo: ... consumption upgrade and policy support, China,s ... the years, with total market size rising from 3.28 ...
(Date:1/15/2014)... AARP Foundation today announced it has established a relief ... cold weather that has gripped much of the nation. AARP ... so to support these emergency relief efforts AARP and AARP ... mean up to $500,000 in aid. The matching program will ...
(Date:1/15/2014)... plc (LSE: SHP, NASDAQ: SHPG ) announces that it ... the announced tender offer for all of the outstanding shares of ... the waiver, the transaction is no longer conditional on OFT approval, ... 2014 following the currently scheduled expiration time, subject to the satisfaction ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... NEW YORK, Oct. 25, 2011 Reportlinker.com ... is available in its catalogue: ... Market Forecasts to 2018 ... - Pipeline Assessment and Market Forecasts to ...
... YORK, Oct. 25, 2011 Reportlinker.com ... report is available in its catalogue: ... Market to 2017 - Patent Expiries ... Aricept, Namenda, Avonex, Rebif and Copaxone ...
Cached Medicine Technology:Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 2Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 3Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 4Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 5Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 6Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 7Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 8Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 9Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 10Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 11Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2018 12Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 2Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 3Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 4Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 5Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 6Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 7Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 8Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 9Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 10Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 11Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 12Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 13Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 14Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth 15
... Merit has a complete offering of ... Performa brands, these catheters are designed with ... shaft strength and better push-ability, and large ... in 4, 5, 6 and 7 French ...
Used to negotiate tortuous vessels....
Used for vascular and non-vascular applications. Tapered fixed core construction provides gradual transition to a flexible,tip. Supplied sterile in peel-open packages. Intended for one-time use....
Used to negotiate tortuous vessels....
Medicine Products: